OCREVUS® (ocrelizumab). Learn about early progression in MS

Early Progression in MS

MS progression begins early, despite initial presentation. Progression can accrue unnoticed and have lasting consequences.

OCREVUS® (ocrelizumab) for your patients with RMS and PPMS

Efficacy and safety in RMS and PPMS

Learn more about OCREVUS (ocrelizumab) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).

OCREVUS® (ocrelizumab) Proposed Mechanism of action

Proposed mechanism of action (MOA) 4

The MOA is presumed to involve immunomodulation through binding to CD20-expressing B cells.

OCREVUS® (ocrelizumab) has more than six years of patient experience

Over 6 years of patient experience 2-4

OCREVUS has over 6 years of patient experience across all clinical trials, including 2 years of controlled and 4+ years of open-label extension study.